Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-15
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter phase I/II study to evaluate the safety and efficacy of sac-TMT plus anlotinib in previously treated mTNBC. The study is expected to enroll up to 59 eligible patients.
Phase:
PHASE1
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital